You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Noninvasive Neural Stimulation Technology

    SBC: Highland Instruments            Topic: 102

    DESCRIPTION provided by applicant The past decade has seen a rapid increase in the application of brain stimulation devices to treat a variety of movement disorders such as Parkinsonandapos s disease PD and other neuropathologies Present noninvasive brain stimulation technologies suffer from fundamental limitations and have yet to reach the level of efficacy of invasive methods such as de ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. PillStream: Agile High-Throughput Assembly of Custom Multi-Medication Packaging

    SBC: ARTAIC, LLC            Topic: NINR

    DESCRIPTION provided by applicant Errors in the administration of medications to residents of long term care facilities LTCFs threaten resident safety and add significant unnecessary costs to the healthcare system Use of unit dose medications that require LTCF staff to manually sort and assemble specific patient medications times per day can result in error rates as high as with of total errors ha ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Closed-Loop Wireless Optical Neuromodulation for Motion Disorders

    SBC: FERRO SOLUTIONS, INC.            Topic: NINDS

    DESCRIPTION provided by applicant Optogenetic tools for activating and silencing specific neurons embedded within dense brain networks in a temporally precise fashion using light are key to understanding the roles that specific neurons play in behavior neural computation and disease In our Phase I SBIR Ferro Solutions and the Boyden lab at MIT collaborated to develop a fully wirelessly powered and ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Antithrombotic Diadenosine Tetraphosphate Analogs

    SBC: GLSynthesis Inc.            Topic: 100

    DESCRIPTION Undesired platelet activation can be result of many common pathologies or interventions Arterial thrombosis and the acute ischemic events that follow such as myocardial infarction and stroke are among the leading causes of death incapacitation and rising health care costs in the developed world Therefore antiplatelet drugs have significant market share and clinical importance ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Narrow-spectrum Agents Acting against Helicobacter pylori

    SBC: Arietis Corporation            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori the causative agent of peptic ulcer and gastric carcinoma Roughly every other person carries the pathogen and there are an estimated cases annually of active infection in the US The currently used triple therapy is a combination of a proton pump inhibitor and broad ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. A CD8+ T cell diagnostic to identify children with pulmonary tuberculosis

    SBC: ViTi, Inc            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB disease which results from infection with Mycobacterium tuberculosis Mtb is a leading cause of infectious morbidity and mortality in children andlt years old worldwide In TB endemic regions in which the vast majority of the worldandapos s annual million adult cases of TB disease reside children andlt years old account for ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Drug Discovery from Slow Growing and Rare Microbial Species

    SBC: NOVOBIOTIC PHARMACEUTICALS, LLC            Topic: NIAID

    DESCRIPTION provided by applicant The overall goal of this project is to discover novel antibiotics to combat important drug resistant pathogens We are running out of treatment options for pathogens such as S aureus MRSA vancomycin resistant Enterococci VRE multidrug resistant P aeruginosa A baumannii ESBL and New Delhi metallo b lactamase producing Enterobacteriaceae and M tuberculosis Only novel ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85. Current FDA-approved drugs only provide symptomatic relief of AD. There is a pressing need to discover newdisease-modifying medications. AD is multifactorial in origin and progression. A drug attenuating several underlying factors is a preferred ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Insulin Pathway Agonist for Alzheimer's Disease

    SBC: MEDCHEM PARTNERS LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Even though the association of -amyloid peptide (A ) deposition and Alzheimer's Disease (AD) underpins the major hypothesis for disease progression and possibly causation and several drugs addressing the formation or removal of -amyloid plaques have entered clinical trials, no effective therapy exists to date for AD. This reality calls for new targets th ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. A Synthetic Human Cytomegalovirus Vaccine Platform

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government